Deutsche Bank AG Cuts Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Deutsche Bank AG trimmed its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 9.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,910 shares of the company’s stock after selling 3,172 shares during the quarter. Deutsche Bank AG owned about 0.07% of Amphastar Pharmaceuticals worth $896,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. grew its position in shares of Amphastar Pharmaceuticals by 13.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company’s stock worth $139,000 after buying an additional 580 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in Amphastar Pharmaceuticals by 21.5% in the first quarter. Arkadios Wealth Advisors now owns 33,966 shares of the company’s stock valued at $985,000 after acquiring an additional 6,002 shares in the last quarter. XTX Topco Ltd purchased a new position in Amphastar Pharmaceuticals in the first quarter worth $532,000. GSA Capital Partners LLP increased its position in shares of Amphastar Pharmaceuticals by 159.8% during the first quarter. GSA Capital Partners LLP now owns 45,297 shares of the company’s stock worth $1,313,000 after purchasing an additional 27,863 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its position in shares of Amphastar Pharmaceuticals by 6,600.0% during the first quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company’s stock worth $46,000 after purchasing an additional 1,584 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Needham & Company LLC raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Tuesday, August 12th. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. JPMorgan Chase & Co. restated a “neutral” rating and set a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.50.

Amphastar Pharmaceuticals Stock Up 2.8%

Amphastar Pharmaceuticals stock opened at $30.50 on Monday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. The business’s 50-day simple moving average is $24.10 and its two-hundred day simple moving average is $25.77. The company has a market cap of $1.42 billion, a PE ratio of 11.42 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.